Afluria Market Growth Through 2030 Creates New Strategic Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Afluria Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
The expansion observed during the historic period is linked to repeated seasonal flu outbreaks, vaccination policies driven by public health initiatives, hospital-led immunization efforts, a growing number of infections leading to hospital admissions, and well-established vaccine production systems.
The expansion observed during the forecast period is driven by a heightened awareness of preventive healthcare, more ambitious vaccination coverage objectives, the broadening of immunization services in retail pharmacies, enhancements in cold chain logistics, and the growing elderly demographic. Key developments shaping this period include a growing need for seasonal flu shots, the enlargement of vaccination initiatives for both adults and children, an intensified emphasis on disease prevention, the increase of state-funded immunization drives, and an upgraded system for vaccine delivery.
Download A Free Sample Report For Comprehensive Market Insights:
Afluria Market Growth Momentum: Which Factors Are Influencing Demand?
The rising incidence of influenza is anticipated to boost expansion in the afluria market moving forward. Influenza, also referred to as the flu, is a contagious respiratory infection caused by influenza viruses, leading to symptoms that range from mild to severe, such as fever, coughing, a sore throat, body aches, and fatigue. This increase in flu cases is driven by factors like greater public awareness of the disease, higher occurrence rates due to viral mutations, and a rising need for vaccines, particularly among at-risk groups such as the elderly. Afluria serves as a preventive vaccine by prompting the immune system to generate antibodies against the flu virus. For example, data from a November 2024 report by the UK Health Security Agency, a government body based in the United Kingdom, showed that by October 16, 2024, influenza positivity climbed to 2.3% in week 41, compared to 2% the prior week, with the highest level at 5.1% observed in individuals aged 5 to 14 years. Consequently, the growing prevalence of influenza is fueling the afluria market’s growth.
The expansion of the geriatric population is forecasted to drive forward momentum in the afluria market. The term geriatric population describes individuals aged 65 and older, who face distinct health issues and difficulties linked to the aging process. This demographic is expanding due to lower birth rates and longer life spans, leading to a bigger share of elderly people in the overall population. Because older adults are especially prone to severe illness and death from influenza, effective vaccination efforts like afluria are essential to safeguard them and lower flu-related health risks. As an illustration, a July 2024 report from the House of Commons Library, a UK government entity, noted that the UK’s population is aging, with roughly 12.7 million people aged 65 and over in 2022, making up 19% of the total; this figure is projected to reach 22.1 million, or 27% of the population, by 2072. Thus, the increasing geriatric population is propelling the afluria market forward.
Afluria Market Segment Outlook: Which Categories Are Expanding The Fastest?
The afluria market covered in this report is segmented –
1) By Formulation: Pre-Filled Syringes, Multi-Dose Vials
2) By Clinical Indication: Influenza Prevention
3) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Government Supplier
4) By End Users: Pediatric, Adult, Geriatric
Afluria Market Trends Reshaping Industry Growth
Key players in the afluria market are emphasizing the development of novel approaches, including nanoparticle-based vaccines, to improve vaccine efficacy, stability, and targeted antigen delivery. A nanoparticle-based vaccine utilizes extremely small particles within the nanometer range, enabling more effective antigen presentation and a reinforced immune response. As an example, in March 2024, Cadila Pharmaceuticals Ltd., a pharmaceutical company headquartered in India, introduced the Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine formulated to protect against seasonal influenza. This vaccine targets four influenza virus strains, encompassing both A and B subtypes, and incorporates essential proteins such as hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) into a single preparation. Such a formulation delivers broader protection, enhanced immunogenicity, and an improved safety record when compared to conventional influenza vaccines.
Afluria Market Key Companies And Competitive Benchmarking
Major companies operating in the afluria market are CSL Seqirus
Access The Complete Afluria Market Report:
Afluria Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the afluria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afluria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
